However, the KM curves in our study revealed that a high expression level of BCL2L1 could be a favorable prognostic factor in both the OS and DFS cohorts, and there was no significant difference between the expression of BCL2L1 in tumor and normal tissues, suggesting that not only expression but also alternative splicing could play crucial roles in the influence of a certain gene related to patient survival. Here, BCL2L1 is linked to neoplasm.